PDS Biotechnology Corporation Recorded Big Gain

PDS Biotechnology Corporation (PDSB:NASDAQ) jumped higher at $6.81, representing a gain of 53.4%. On Mon 08 Feb 21, PDSB:NASDAQ touched a New 2-Week High of $4.44. The stock appeared on our News Catalysts scanner on Wed 03 Feb 21 at 04:55 PM in the 'BIOTECH' category. From Mon 25 Jan 21, the stock recorded 70.00% Up Days and 63.64% Green Days

About PDS Biotechnology Corporation (PDSB:NASDAQ)

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.